Dr. Chien is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
David Chien M.D.
Westlake Village, CA 91362- Is this information wrong?
Summary
- https://www.linkedin.com/in/davidchienmd/
https://www.krystalbio.com/about-us/leaders/
Education & Training
- Johns Hopkins University School of MedicineFellowship, PET/CT, 2010 - 2011
- Johns Hopkins UniversityResidency, Nuclear Medicine, 2007 - 2010
- New York-Presbyterian/QueensInternship, Internal Medicine, 2006 - 2007
- University of California, Davis, School of MedicineClass of 2006
Certifications & Licensure
- CA State Medical License 2011 - 2025
- PA State Medical License 2010 - 2012
- NY State Medical License 2010 - 2012
- American Board of Nuclear Medicine Nuclear Medicine
- Certification Board of Nuclear CardiologyNuclear Cardiology
Awards, Honors, & Recognition
- National Research Service Award NIH, 2010
- Young Investigator Award Society of Nuclear Medicine, 2009
- Morton Levitt Research Award University of California Davis, 2004
Clinical Trials
- A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 May 21
- A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 Start of enrollment: 2013 Dec 01
- A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsBempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhur...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
- 5 citationsBempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal...> ;European Urology. 2022 Oct 1
- 6 citationsPIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, Dirk Schadendorf, Genevieve Boland, Jeffrey Weber, Karl D Lewis, Daniel Johnson, Gareth Rivalland, Adnan...> ;Future Oncology. 2022 Mar 1
- Join now to see all
Journal Articles
- Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trialZegers CM, van Elmpt W, Szardenings K, Kolb H, Waxman A, Subramaniam RM, Moon DH, Brunetti JC, Srinivas SM, Lambin P, Chien D, Eur J Nucl Med Mol Imaging, 1/1/2015
- Optimum lean body formulation for correction of SUV in PET imagingTahari AK, Chien D, Azadi JR, Wahl RL, J Nucl Med, 1/1/2014
- Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T808Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb H, J Alzheimers Dis, 1/1/2013
- Join now to see all
Abstracts/Posters
- Hypoxia [18F] HX4 PET imaging in patients with head and neck cancer: repeatability and stability during radiotherapyZegers C, Van Elmpt W, Hoebers F, Chien D, Lambini P, Radiotherapy and Oncology, 1/1/2015
- Phase 1 preliminary safety, efficacy, and biomarker data from venetoclax (ABT-199/GDC-0199) + bendamustine and rituximab in R/R non-Hodgkin’s lymphomade Vos S, Swinnen L, Kozloff M, Wang D, Reid E, Nastoupil L, Fowler N, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Agarwal S, Ross J, Punnoose E, McKeegan E, Hei..., Hematol Oncol, 1/1/2015
- A dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine and rituximab in patients with relapsed/refractory non-Hodgkin’s lymphomade Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Salem A, Heitner-Enschede S, Ricker JL, Chien D, Humerickho..., Haematologica, 1/1/2015
- Join now to see all
Professional Memberships
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/davidchienmd/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: